Advertisement

Advertisement

GB:0L35 Stock Latest News

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

The FlyPrivate Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform

PremiumRatings

Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform

7d ago

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

PremiumThe Fly

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

7d ago

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

PremiumThe Fly

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

8d ago

Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged

PremiumRatings

Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged

8d ago

H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss

PremiumThe FlyH.C. Wainwright reiterates Sell on Sarepta after Novartis study miss

8d ago

Unusually active option classes on open August 7th

The Fly

Unusually active option classes on open August 7th

1M ago

Sarepta Therapeutics Balances Profit Gains With Revenue Strain

Company Announcements

Sarepta Therapeutics Balances Profit Gains With Revenue Strain

1M ago

Sarepta price target lowered to $35 from $37 at Oppenheimer

PremiumThe Fly

Sarepta price target lowered to $35 from $37 at Oppenheimer

1M ago

Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged

PremiumRatings

Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged

1M ago

Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook

PremiumRatings

Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook

1M ago

Sarepta reports Q2 adjusted EPS 64c, consensus 49c

PremiumThe Fly

Sarepta reports Q2 adjusted EPS 64c, consensus 49c

1M ago

Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet

PremiumPre-EarningsSarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet

1M ago

Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts

The Fly

Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts

2M ago

Sarepta Therapeutics Appoints Michael Severino as CEO

Company Announcements

Sarepta Therapeutics Appoints Michael Severino as CEO

2M ago

Sarepta appoints Severino as Chief Executive Officer

PremiumThe Fly

Sarepta appoints Severino as Chief Executive Officer

2M ago

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13

PremiumRatings

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13

2M ago

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

PremiumThe Fly

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

2M ago

Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls

PremiumThe Fly

Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls

2M ago

Sarepta price target lowered to $20 from $23 at Piper Sandler

PremiumThe FlySarepta price target lowered to $20 from $23 at Piper Sandler

2M ago

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

The Fly

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

2M ago

H.C. Wainwright says Sarepta news does not signal full approvals

The Fly

H.C. Wainwright says Sarepta news does not signal full approvals

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >